Tag: Tepotinib
Merck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skippin

Merck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skippin

- Investigational oral MET inhibitor has previously received SAKIGAKE 'fast-track' regulatory designation in Japan - MET exon 14 skipping alterations and MET amplifications ...

Lees verder
Merck Presents Updated Results for Investigational Therapy Tepotinib Demonstrating Durable Clinical Response in Patients with Advanced NSCLC with

Merck Presents Updated Results for Investigational Therapy Tepotinib Demonstrating Durable Clinical Response in Patients with Advanced NSCLC with

ASCO Abstract # Tepotinib (MET kinase inhibitor): 9005 Not intended for UK- , Canada- or US-based media DARMSTADT, Germany, June 3, 2019 /PRNewswire/ -- -- ...

Lees verder
Merck Presents Update on Tepotinib in Advanced Lung Cancer at ASCO 2018

Merck Presents Update on Tepotinib in Advanced Lung Cancer at ASCO 2018

DARMSTADT, Germany, June 3, 2018 /PRNewswire/ -- ASCO Abstract # Tepotinib (c-Met kinase inhibitor): 9082, 9016; M7824 (TGF-ss trap/anti-PD-L1): 3007, 9017, 2566; M2698 (dual ...

Lees verder
Merck Receives Fast-Track Designation for Tepotinib in Non-Small Cell Lung Cancer in Japan

Merck Receives Fast-Track Designation for Tepotinib in Non-Small Cell Lung Cancer in Japan

DARMSTADT, Germany, March 27, 2018 /PRNewswire/ -- Not intended for UK- or US-based media  - Japanese Ministry of Health, Labour and Welfare Grants SAKIGAKE ...

Lees verder
BizPress.nl